In light of recent findings, would you consider prescribing dutasteride to men with low-risk prostate cancer to reduce their risk of PCa progression?

Share this article:

A randomized, double-blind study published recently in The Lancet showed that men on active surveillance for low-risk prostate cancer (PCa) who received the 5α-reductase inhibitor dutasteride for three years had a significant 38% decreased risk of PCa progression compared with men who took placebo. The investigators concluded that their findings “show that dutasteride could be a beneficial adjunct to active surveillance for men with low-risk prostate cancer, delaying their time to pathological progression and initiation of primary therapy.”

Renal & Urology News would like to ask its urologist readers the following question.


Leave a comment below to explain your choice.
Share this article:
You must be a registered member of RUN to post a comment.

Sign Up for Free e-newsletters

More in Physician Polls

Has the proportion of your patients undergoing prostate brachytherapy been declining?

Has the proportion of your patients undergoing prostate ...

Prostate cancer patients undergoing radical prostatectomy increased by double digits while those undergoing brachytherapy decreased.

Are statins a valid approach for preventing contrast-induced nephropathy (CIN)?

Are statins a valid approach for preventing contrast-induced ...

Patients treated with statins have a significant 55% decreased odds of contrast-induced nephropathy.

Are you surprised that targeted therapeutics for metastatic renal cell carcinoma (RCC) have not improved survival?

Are you surprised that targeted therapeutics for metastatic ...

A study found that targeted therapeutic agents for treating metastatic RCC has not led to an improvement in survival rates.